(Jun. 3, 2026 / TPS-IL)
Israeli-led researchers have identified a previously underappreciated mechanism that may explain why many prostate cancers stop responding to standard hormone therapy, potentially opening the door to new treatment strategies.
The study, led by Prof. Yosef Yarden of the Weizmann Institute of Science, focuses on a genetic alteration known as a gene fusion, in which two separate genes abnormally join to form a single hybrid gene. The mutation is found in about half of all prostate cancer cases.
